Article Information
PubMed
Published By
History
- Received February 11, 2014
- Revision received April 23, 2014
- Accepted May 28, 2014
- First published July 9, 2014.
- Version of record published July 9, 2014.
Copyright & Usage
Copyright © 2014 the authors 0270-6474/14/349261-07$15.00/0
Author Information
Author contributions
Author contributions: S.M.P., F.R.C., A.F., and D.J.L. designed research; S.M.P. and F.R.C. performed research; S.M.P. and D.J.L. analyzed data; S.M.P., F.R.C., A.F., and D.J.L. wrote the paper.
Disclosures
- Received February 11, 2014.
- Revision received April 23, 2014.
- Accepted May 28, 2014.
This work was supported by NIH Grants R01 MH082933 (A.F.), R01 MH090067 (D.J.L.), and F31 MH098564 (S.M.P.).
S.M.P. and F.R.C. declare no competing financial interests. A.F. has served on advisory boards for Lundbeck, Takeda Pharmaceuticals International, and Eli Lilly; and as a consultant for Dey Pharmaceuticals. Previously, A.F. had received financial compensation as a consultant for Cyberonics and had also obtained grant support from them for a preclinical study. D.J.L. reports receiving consulting fees from Dey Pharmaceuticals.
- Correspondence should be addressed to Dr Daniel J. Lodge, University of Texas Health Science Center at San Antonio, Department of Pharmacology, 7703 Floyd Curl Drive, MC 7764, San Antonio, TX 78229. LodgeD{at}uthscsa.edu
Online Impact